In the context of the UK Health Services Authority to expand the Cancer Vaccine Launch Pad program, advanced skin cancer patients in the Kingdom will have a quick opportunity to obtain a new cancer vaccine, as part of an experiment that the authority conducts.
7 sites for the arrival of patients in principle, and it is expected to refer the first patients next month.
The program for launching the cancer vaccine launch enables qualified patients to participate in vaccine development studies in the nearest participating hospital in the study, according to the British newspaper Guardian. The initiative aims to provide cancer treatments to 10,000 patients in England, in the Kingdom by 2030.
The vaccine – known as “ICIP1” (ISCIB1+) – helps the immune system to identify melanin skin cancer cells, thus better responding to immunotherapy.
Skin cancer is the fifth most common type of cancer in the UK, with about 4% of all new cases.
The program has already helped thousands of patients with the National Health Services Authority to participate in vaccine experiments dedicated to bowel cancer, as more than 350 people were chosen to participate in experiments, and the program has now expanded to include an experiment to treat skin cancer. It aims to provide personal cancer treatments for 10,000 patients in England by 2030.